Ranbaxy's Patent Litigations in the United States |
ICMR HOME | Case Studies Collection
» Economics
Case Studies Please note: This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source. |
||||
“We take legal advice and respond appropriately. But we will not lose sleep over it [patent litigation]. It is something that one has to live with, if one has to do business in the US.”1 – D. S. Brar, CEO, Ranbaxy Laboratories Limited in 2002. “It's a simple business philosophy. If you play enough of these, you will win some.”2 – Cameron Reid, President, Dr. Reddy's Laboratories Inc., US, in 2003 commenting on patent challenges to branded drugs. “We will continue to defend against any and all patent challenges that seek to undermine our mission of finding new therapeutic innovations for the patients we serve.”3 – Hank McKinnell, Chairman and Chief Executive Officer, Pfizer Inc.4 after defeating Ranbaxy's patent challenge to Lipitor in the US on December 16, 2005. Introduction
It was not the first time that Ranbaxy had to face an adverse ruling in a patent challenge.
Ranbaxy's Patent Litigations in the United States - Next Page>> 1]
P. T. Jyothi Datta, “Litigation in large doses,” |
Case Studies Links:-
Case Studies,
Short Case Studies,
Simplified Case Studies.
Other Case Studies:-
Multimedia Case Studies,
Cases in Other Languages.
Business Reports Link:-
Business Reports.
Books:-
Textbooks,
Work Books,
Case Study Volumes.